NTU Singapore scientists invent coin-sized device to isolate blood plasma

New device rapidly isolates blood plasma for diagnostics and precision medicine

26 Mar 2024
Jessica Calvey
Product and Reviews Admin Assistant
(L-R) NTU Assoc Prof Hou Han Wei, Research Fellow Dr. Leong Sheng Yuan, Research Engineer Ms Lok Wan Wei, and Tan Tock Seng Senior Consultant, Assoc Prof Rinkoo Dalan, with the ExoArc prototype system.

NTU scientists have developed ExoArc, a coin-sized chip device that can directly isolate blood plasma from a tube of blood in just 30 minutes, which is more convenient and user-friendly when compared to the current gold standard, multi-step centrifugation process.

With just a single step, ExoArc can achieve high blood plasma purity by removing more than 99.9% of blood cells and platelets precisely and gently, which will greatly speed up clinical analysis and screening for biomarkers that are tell-tale signs specific to certain cancers and diseases.

As a proof-of-concept, the team built a portable prototype device to house the ExoArc chip, which has a large touch-screen interface to adjust settings, as well as internal pumps and piping for the processing of blood samples and collection of the isolated blood plasma.

Together with clinician-scientists from the National Cancer Centre Singapore (NCCS), Tan Tock Seng Hospital (TTSH), and the Agency for Science, Technology and Research (A*STAR), the team clinically validated ExoArc by analysing the microRNA profile of blood plasma in healthy people and cancer patients using a biomarker panel and found it was able to diagnose non-small cell lung cancer with high accuracy.

In another practical use-case application for precision medicine, the purified blood plasma can also be used to screen and differentiate healthy individuals from those with type 2 diabetes.

ExoArc currently has two patent applications filed through NTUitive, NTU’s innovation and enterprise company and its study findings have been published recently in ACS Nano, a journal under the American Chemical Society.

The development of ExoArc is backed by a Proof-of-Concept and Proof-of-Value grant from the NTUitive Gap Fund, under the NTU Innovation and Entrepreneurship initiative.

Want the latest clinical science news straight to your inbox? Become a SelectScience member for free today>>

Links

Tags